Inflammation and Immunity
Steering Committee

The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

Thierry Sornasse, Ph.D., AbbVie (Co-Chair)

David Fox, M.D., University of Michigan (Co-Chair)

Alexandre Akoulitchev, M.A., Ph.D., Oxford Biodynamics

Tara Altepeter, M.D., FDA/CDER

Anne-Christine Bay-Jensen, Ph.D., Nordic Biosciences A/S

Kristina Beeler, Ph.D., Ms.C., Biognosys

Robert Benschop, Ph.D., Eli Lilly

Maria Bettinotti, Ph.D., Association of Molecular Pathology (AMP)

Jonathan Blackburn, Ph.D., Sengenics

Preethi Chander, Ph.D., NIDCR/NIH

Kelly Chun, Ph.D., LabCorp

Albert Crescenzo, Ph.D., Clarivate

Carolyn Cuff, Ph.D., Janssen

Sahar Dawisha, M.D., FDA/CDRH

Betty Diamond, Ph.D., Feinstein Institute

Renee Donahue, Ph.D., NIH/NCI

Edward Driggers, Ph.D., General Metabolics

Carol Feghali-Bostwick, Ph.D., National Scleroderma Foundation

Chao Jiang, Ph.D., NIAID/NIH

Thomas Fuerst, Ph.D., Clario

Rebecca Fuldner, Ph.D., NIH/NIA

Ed Driggers, Ph.D., General Metabolics

Mireia Guerau, PharmD, Ph.D., NIH/NIAID

Arcan Guven, Ph.D., Biogen

Kathy Hammitt, M.A., Sjogren’s Foundation

Stephanie Hennek, Ph.D., PathAI

Andrea Hooper, Ph.D, Regeneron

Kathy Jung, Ph.D., NIH/NIAAA

Ernst Kriehuber, M.D., UCB

David Martin, M.D., Pfizer

Russell McBride, Ph.D., MPH, Icahn School of Medicine at Mount Sinai

Bruce McManus, M.D., Ph.D., University of British Columbia

Alan Moss, M.D,. Crohn’s & Colitis Foundation of America

Sumanta Mukherjee, Ph.D., GlaxoSmithKline

Tanya Nguyen, Ph.D., Sapient

Nikolay Nikolov, M.D., FDA/CDER

Mariaelena Occhipinti, M.D., Ph.D., Radiomics

Heiyoung Park, Ph.D., NIAMS/NIH

Jane Parnes, M.D., Amgen

Brian Porter, M.D., Ph.D., M.P.H., M.B.A., Novartis

Josh Porter, Olink Proteomics

John Reveille, M.D., University of Texas Health Science Center (Houston)

Lisa Rider, M.D., NIH/NIEHS

Jane Salmon, M.D., Hospital for Special Surgery

Johannes Scheid, M.D., Ph.D., Merck

Maggie Scully, Ph.D., Frederick National Laboratory for Cancer Research

Susana A. Serrate-Sztein, M.D., NIH/NIAMS

Lisa Spain, Ph.D., NIH/NIDDK

Emily Boyd Stormoen, Arthritis National Research Foundation

Paresh Thakker, Ph.D., Takeda

Candance Tingen, Ph.D., NIH/NICHD

Maria Vassileva, Ph.D., Arthritis Foundation

Sudha Visvanathan, Ph.D., Boehringer Ingelheim

Andrea Wagenfeld, Ph.D., Bayer

Tony Wagner, Ph.D., Jazz Pharmaceuticals

Joe Wang, Ph.D., NIH/NIAAA

Ilan Wapinski, Ph.D., Sanofi

Michael Weisman, M.D., Cedars-Sinai Medical Center

Mary Wheatley, National Scleroderma Foundation

Michael Whitfield, Ph.D., Dartmouth Geisel School of Medicine

Joel Wommack, Ph.D., SomaLogic